key inclusion criteria: * subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form. consent must be performed per institutional regulations. * age of ≥ 18 years * positive sars-cov-2 (2019-ncov) test within 14 days prior to randomization * hospitalized for sars-cov-2 (2019-ncov) * bilateral pneumonia on chest x-ray or computed tomography * clinical laboratory results indicative of hyper-inflammation within 7 days prior to randomization * cohort 1: receiving any form of non-invasive ventilation or oxygenation to maintain spo2 ≥ 92% and non-mechanically ventilated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation) * cohort 2: recently ventilated with mechanical ventilation beginning within 48 hours prior to randomization key

key inclusion criteria: * subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form. consent must be performed per institutional regulations. * age of ≥ 18 years * positive sars-cov-2 (2019-ncov) test within 14 days prior to randomization * hospitalized for sars-cov-2 (2019-ncov) * bilateral pneumonia on chest x-ray or computed tomography * clinical laboratory results indicative of hyper-inflammation within 7 days prior to randomization * cohort 1: receiving any form of non-invasive ventilation or oxygenation to maintain spo2 ≥ 92% and non-mechanically ventilated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation) * cohort 2: recently ventilated with mechanical ventilation beginning within 48 hours prior to randomization key

key inclusion criteria: subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form. consent must be performed per institutional regulations. age of ≥ 18 years positive sars-cov-2 (2019-ncov) test within 14 days prior to randomization hospitalized for sars-cov-2 (2019-ncov) bilateral pneumonia on chest x-ray or computed tomography clinical laboratory results indicative of hyper-inflammation within 7 days prior to randomization cohort 1: receiving any form of non-invasive ventilation or oxygenation to maintain spo2 ≥ 92% and non-mechanically ventilated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation) cohort 2: recently ventilated with mechanical ventilation beginning within 48 hours prior to randomization key

key inclusion criteria: subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form. consent must be performed per institutional regulations. age of ≥ 18 years positive sars-cov-2 (2019-ncov) test within 14 days prior to randomization hospitalized for sars-cov-2 (2019-ncov) bilateral pneumonia on chest x-ray or computed tomography clinical laboratory results indicative of hyper-inflammation within 7 days prior to randomization cohort 1: receiving any form of non-invasive ventilation or oxygenation to maintain spo2 ≥ 92% and non-mechanically ventilated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation) cohort 2: recently ventilated with mechanical ventilation beginning within 48 hours prior to randomization key

key inclusion criteria: - subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form - positive sars-cov-2 (2019-ncov) test within 14 days prior to randomization - hospitalized for sars-cov-2 - bilateral pneumonia on chest x-ray or computed tomography - clinical laboratory results indicative of hyper-inflammation - cohort 1: receiving any form of oxygenation or niv to maintain spo2 ≥ 92% and not-intubated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation) - cohort 2: recently ventilated with mechanical ventilation prior to randomization key

key inclusion criteria: - subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form - positive sars-cov-2 (2019-ncov) test within 14 days prior to randomization - hospitalized for sars-cov-2 - bilateral pneumonia on chest x-ray or computed tomography - clinical laboratory results indicative of hyper-inflammation - cohort 1: receiving any form of oxygenation or niv to maintain spo2 ≥ 92% and not-intubated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation) - cohort 2: recently ventilated with mechanical ventilation prior to randomization key

key inclusion criteria: - subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form - positive sars-cov-2 (2019-ncov) test within 14 days prior to randomization - hospitalized for sars-cov-2 - bilateral pneumonia on chest x-ray or computed tomography - active fever or recently documented fever within 72 hours prior to randomization - clinical laboratory results indicative of hyper-inflammation - cohort 1: receiving any form of oxygenation or niv to maintain spo2 ≥ 92% and not-intubated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation) - cohort 2: recently ventilated with mechanical ventilation prior to randomization key

key inclusion criteria: - subject (or legally authorized representative) is able and willing to provide informed consent, which includes compliance with study requirements and restrictions listed in the consent form - positive sars-cov-2 (2019-ncov) test within 14 days prior to randomization - hospitalized for sars-cov-2 - bilateral pneumonia on chest x-ray or computed tomography - active fever or recently documented fever within 72 hours prior to randomization - clinical laboratory results indicative of hyper-inflammation - cohort 1: receiving any form of oxygenation or niv to maintain spo2 ≥ 92% and not-intubated (examples include nasal cannula, face mask, venturi mask, high-flow nasal cannula, or non-invasive positive pressure ventilation) - cohort 2: recently ventilated with mechanical ventilation prior to randomization key